IWAA 2022 Annual Meeting

August 11, 2022 to August 13, 2022

The 2022 annual meeting of the Intermountain West Allergy Association (IWAA) will take place in Coeur d'Alene, Idaho on August 11-13 and be attended by 60 clinicians, including allergists-immunologists, fellows in accredited allergy/immunology training programs, allied health professionals, and primary care physicians who care for allergy patients. The purpose of IWAA’s annual meeting is to improve patient outcomes by increasing attendees’ knowledge of the latest research, guidelines, and expert opinion relevant to the diagnosis and management of patients with allergy, asthma, and immunological disorders. This year, the IWAA annual meeting’s theme is "An Allergy Science Potpourri." It will include two full days of sessions led by nationally recognized experts on topics such as food allergy treatment, severe asthma management, adult vaccination schedules, long COVID-19, chronic spontaneous Urticaria, understanding the immunology of HIV and eosinophilic gastrointestinal disorders.  In addition, there will be a Practice Management Symposium.  The small, intimate meeting atmosphere allows ample opportunity for knowledge sharing and collaboration among attendees and presenters..

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunology and Intermountain West Allergy Association. The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.”

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 15 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity the participant should be able to:

1. Summarize recent data, expert opinion and clinical practice guidelines on the treatment of allergic and immunological disease.    
2  Describe the safety and efficacy profiles of established and emerging therapies for the treatment of allergic and immunological diseases.
3. Apply knowledge of the pathophysiology of allergic and immunological diseases to clinical decision-making. 

    Additional information
    Disclosure: 

    As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

    Ambulatory procedure centers
    Blood banks
    Diagnostic labs that do not sell proprietary products
    Electronic health records companies
    Government or military agencies
    Group medical practices
    Health law firms
    Health profession membership organizations
    Hospitals or healthcare delivery systems
    Infusion centers
    Insurance or managed care companies
    Nursing homes
    Pharmacies that do not manufacture proprietary compounds
    Publishing or education companies
    Rehabilitation centers
    Schools of medicine or health science universities
    Software or game developers


    The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

    Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

    Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been mitigated.

    Course summary
    Available credit: 
    • 15.00 AMA PRA Category 1 Credit™
    • 15.00 Attendance
    Course opens: 
    08/11/2022
    Course expires: 
    08/12/2023
    Event starts: 
    08/11/2022 - 4:30pm CDT
    Event ends: 
    08/13/2022 - 5:15pm CDT
    Rating: 
    0

    Doug Huneywell

    Planner

    No Relevant Financial Relationships with ineligible companies to disclose.

    Ron England, M.D.

    Board of Director

    No Relevant Financial Relationships with ineligible companies to disclose

    Richard Henry, M.D.

    Board of Director

    No Relevant Financial Relationships with ineligible companies to disclose

    Carl Thornblade, M.D.

    Board of Director

    Regeneron, Ind. Contractor

    Dermavant Sciences – Ind. Contractor

    Novartis – Ind. Contractor

    Verona – Ind. Contractor

    Satsuma – Ind. Contractor

    TEVA – Ind. Contractor

    Genentech – Ind. Contractor

    Shionugi – Ind. Contractor

    Bellus Health – Ind. Contractor

    Galderma – Ind. Contractor

    Bayer – Ind. Contractor

    Greg Wickern, M.D.

    Board of Director

    No Relevant Financial Relationships with ineligible companies to disclose

    Allen Kaplan, M.D.

    Speaker

    BioCryst – Advisor, Speaker

    Genentech – Advisor

    Pharming – Advisor, Speaker

    Abb-RISA – Advisor

    Takeda – Advisor, Speaker

    Samuel Louie, M.D.

    Speaker

    AstraZeneca – Advisor, Speaker

    Boehringer Ingelheim – Advisor, Speaker

    Genentech – Advisor, Speaker

    GSK - Advisor, Speaker

    Regeneron – Advisor, Speaker

    Sanofi Genzyme – Advisor, Speaker

    Amgen - Speaker

    Bryan Martin, D.O.

    Speaker

    ALK - Advisor

    Michael Peluso, M.D.

    Speaker

    No Relevant Financial Relationships with ineligible companies to disclose

    James Thompson, PhD

    Speaker

    No Relevant Financial Relationships with ineligible companies to disclose

    Amiko Uchida, M.D.

    Speaker

    Sanofi-Regeneron – Advisor

    Takeda - Researche

    Available Credit

    • 15.00 AMA PRA Category 1 Credit™
    • 15.00 Attendance
    Please login or create an account to take this course.